With the rapid development of epidermal growth factor receptor (EGFR) gene testing of lung adenocarcinoma patients has been routinely carried out, EGFR mutations are also possible for some small samples of non-smoking female lung squamous cell carcinoma patients. This increases the opportunity for targeted therapy for this group of patients. However, drug resistance in patients with lung squamous cell carcinoma during targeted therapy is an important factor affecting subsequent treatment. There are multiple mechanisms of acquired drug resistance in targeted therapy, and the alteration of mesenchymal-epithelial transition factor (MET) signaling pathway is one of the common mechanisms of drug resistance. At present, some selective tyrosine kinase inhibitors (TKIs) of MET has been approved for non-small cell lung cancer with MET gene 14 exon skipping mutation, such as Glumetinib, Savolitinib, Tepotinib, Capmatinib, etc. Drugs that target secondary MET amplification are still in clinical trials. This paper retrospectively analyzed the clinical data of a female patient with EGFR-TKIs resistant secondary MET amplified squamous cell lung cancer, and reviewed relevant literature to explore how to optimize the treatment of lung squamous cell carcinoma patients with EGFR mutation, so as to provide clinical reference for the diagnosis and treatment of such patients. .
【中文题目：EGFR-TKIs耐药继发MET基因扩增 肺鳞癌1例报告并文献复习】 【中文摘要：肺腺癌患者目前已常规开展表皮生长因子受体（epidermal growth factor receptor, EGFR）的基因检测，而部分小样本的不吸烟的女性肺鳞癌患者也有EGFR突变的可能，肺癌靶向治疗的快速发展为这一类患者增加了靶向治疗的机会。然而肺鳞癌患者行靶向治疗期间出现耐药是影响后续治疗的重要因素。靶向治疗获得性耐药有多种机制，间充质细胞上皮转化因子（mesenchymal-epithelial transition factor, MET）信号通路的改变是其中常见的耐药机制之一。目前，一些MET的选择性酪氨酸激酶抑制剂（tyrosine kinase inhibitors, TKIs）已获批用于伴 MET基因14外显子跳跃突变的非小细胞肺癌，如谷美替尼、塞沃替尼、特泊替尼、卡马替尼等，而针对继发MET基因扩增的药物尚处于临床试验阶段。本文通过回顾性分析1例EGFR-TKIs耐药继发MET基因扩增女性肺鳞癌患者的临床资料，并复习相关文献，探讨如何优选具有EGFR突变的肺鳞癌患者的治疗方案，为该类患者的诊疗提供临床借鉴及参考。 】 【中文关键词：肺肿瘤；EGFR-TKIs；MET；肺鳞癌】.
Keywords: EGFR-TKIs; Lung neoplasms; MET; Squamous cell lung cancer.